Epkinly Granted Accelerated FDA Approval for Lymphoma
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
MONDAY, May 22, 2023 -- The U.S. Food and Drug Administration has granted accelerated approval to Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma.
The recommended regimen consists of Epkinly administered subcutaneously in 28-day cycles until disease progression or unacceptable toxicity. Step-up dosing is recommended with cycle 1 (0.16 mg on day 1; 0.8 mg on day 8; and 48 mg on day 15 and day 22), followed by fixed dosing of 48 mg weekly dosing during cycles 2 through 3, every other week during cycle 4 through 9, and then every four weeks on day 1 of subsequent cycles.
Approval was based on trial data from 148 patients with relapsed or refractory DLBCL. The overall response rate, assessed by an independent review committee, was 61 percent, with 38 percent of patients achieving complete responses. During a median follow-up of 9.8 months among responders, the estimated median duration of response was 15.6 months.
The prescribing information has a boxed warning for serious or life-threatening cytokine release syndrome (CRS) and life-threatening or fatal immune effector cell-associated neurotoxicity syndrome. Infections and cytopenias are included as warnings and precautions. The most common (≥20 percent) adverse reactions were CRS, fatigue, musculoskeletal pain, injection site reactions, pyrexia, abdominal pain, nausea, and diarrhea, while the most common grade 3 to 4 laboratory abnormalities (≥10 percent) included decreases in lymphocyte count, neutrophil count, white blood cell count, hemoglobin, and platelets.
Accelerated approval of Epkinly was granted to Genmab.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2023
Read this next
CD7 CAR T-Cell Therapy, Stem-Cell Transplant Beneficial for CD7-Positive Tumors
THURSDAY, April 25, 2024 -- For patients with relapsed or refractory CD7-positive leukemia or lymphoma, sequential CD7 chimeric antigen receptor (CAR) T-cell therapy followed by...
Second Primary Malignancy Risk Increased After Cutaneous B-Cell Lymphoma
WEDNESDAY, April 3, 2024 -- Patients with primary cutaneous B-cell lymphomas (PCBCLs) have an increased risk for second primary malignancies (SPMs), according to a study published...
Survival 21 Percent a Year After ICU Discharge for Blood Cancer Patients
THURSDAY, March 21, 2024 -- For hematologic malignancy (HM) patients admitted to the intensive care unit (ICU), survival is 49 percent at seven days and 21 percent at 12 months...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.